A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Inc.
Eisai Inc.
Eli Lilly and Company
Eli Lilly and Company
Hunan Cancer Hospital
University of California, San Francisco
Kyowa Kirin Co., Ltd.
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Novartis
Novartis
Pfizer
Taizhou EOC Pharma Co., Ltd.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center